Immunotherapy top up

Cancer vaccine company immatics biotechnologies GmbH may have raised its last private financing round, as investors gave it enough cash to submit regulatory applications for lead program IMA901.

Last week, immatics raised €12 million ($16.3 million) in the first tranche of a €34 million ($46.1 million) series D round. CEO Paul Higham told BioCentury the additional cash will finance the company beyond 2015, when final Phase III data are expected for IMA901 in renal cell carcinoma (RCC). The funds will support regulatory submissions in the U.S. and Europe for the vaccine containing tumor-associated peptides (TUMAPs)...